- Home
- UFI vs ATYR Comparison
UFI vs ATYR Comparison
Compare UFI & ATYR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- UFI
- ATYR
- Stock Information
- Founded
- UFI 1969
- ATYR 2005
- Country
- UFI United States
- ATYR United States
- Employees
- UFI N/A
- ATYR N/A
- Industry
- UFI Textiles
- ATYR Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- UFI Consumer Discretionary
- ATYR Health Care
- Exchange
- UFI Nasdaq
- ATYR Nasdaq
- Market Cap
- UFI N/A
- ATYR 228.1M
- IPO Year
- UFI N/A
- ATYR 2015
- Fundamental
- Price
- UFI $5.68
- ATYR $3.45
- Analyst Decision
- UFI
- ATYR Strong Buy
- Analyst Count
- UFI 0
- ATYR 4
- Target Price
- UFI N/A
- ATYR $19.25
- AVG Volume (30 Days)
- UFI 58.2K
- ATYR 828.2K
- Earning Date
- UFI 01-29-2025
- ATYR 11-07-2024
- Dividend Yield
- UFI N/A
- ATYR N/A
- EPS Growth
- UFI N/A
- ATYR N/A
- EPS
- UFI N/A
- ATYR N/A
- Revenue
- UFI $590,737,000.00
- ATYR $235,000.00
- Revenue This Year
- UFI $11.45
- ATYR N/A
- Revenue Next Year
- UFI $6.84
- ATYR $1,200.54
- P/E Ratio
- UFI N/A
- ATYR N/A
- Revenue Growth
- UFI 1.35
- ATYR N/A
- 52 Week Low
- UFI $5.41
- ATYR $1.38
- 52 Week High
- UFI $7.91
- ATYR $3.98
- Technical
- Relative Strength Index (RSI)
- UFI 48.35
- ATYR 60.79
- Support Level
- UFI $5.50
- ATYR $3.28
- Resistance Level
- UFI $5.87
- ATYR $3.98
- Average True Range (ATR)
- UFI 0.13
- ATYR 0.22
- MACD
- UFI 0.05
- ATYR 0.04
- Stochastic Oscillator
- UFI 48.84
- ATYR 62.00
About ATYR aTyr Pharma Inc. Common Stock
aTyr Pharma Inc is a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform. The company has concentrated its research and development efforts on a newly discovered area of biology, the extracellular functionality and signaling pathways of tRNA synthetases. Its primary focus is efzofitimod, a clinical-stage product candidate which targets NRP2 to resolve chronic inflammation that can lead to fibrosis. Efzofitimod has a novel mechanism of action for potentially treating lung inflammation and fibrosis.